FDA approves Enspryng for neuromyelitis optica spectrum diso
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The FDA has approved Enspryng for adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, according to a Genentech press release.

Enspryng (satralizumab-mwge) is the first subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) that can be administered by the patient or caregiver at home after receiving training from a health care provider. The treatment is given every 4 weeks after the initial loading dose. It is designed to target and inhibit interleukin-6 receptor activity. FDA approval was based on results from two randomized, controlled phase 3 clinical trials. In the SAkuraStar and SAkuraSky studies, the therapy showed sustained efficacy and a favorable safety profile. Results were sustained for 96 weeks, and study subjects demonstrated a reduced risk for relapse compared with subjects treated with a placebo when used with baseline immunosuppressant therapy.

The most common adverse effects include nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue and nausea.

Source: https://www.healio.com/news/ophthalmology/20200817/fda-approves-enspryng-for-neuromyelitis-optica-spectrum-disorder
Like
Comment
Share